Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy

Acta Derm Venereol. 2015 Feb;95(2):233-4. doi: 10.2340/00015555-1874.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Biopsy
  • Brentuximab Vedotin
  • Humans
  • Immunoconjugates / therapeutic use*
  • Immunohistochemistry
  • Ki-1 Antigen / analysis*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / immunology
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Male
  • Middle Aged
  • Remission Induction
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Ulcer / drug therapy*
  • Skin Ulcer / immunology
  • Skin Ulcer / pathology
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin